In Search of the ‘Bad Guy’
Fighting for patient affordability doesn’t necessarily require a scapegoat.
Affordability: Who's Responsible?
The debate continues as to how government payers should weigh covering healthcare needs versus other budget items.
Are CEOs Getting Access Right?
A dive into the issue of evidence gaps, plus the case for a chief access officer.
IRA Journey Update
The latest on its implementation—and the implications for biopharma.
Assessing Drug Pricing in Europe
How various factors are affecting the amount of funds allocated to healthcare.
Introducing Value & Access
New Pharma Commerce column addresses the relevance of pricing.
The IRA is Industry's Wake-up Call
Exploring the legislation's diverging requirements between regulatory agencies and global payers, and its impact on the commercial results of biopharma companies
Unpacking Risk Sharing and Alternative Pricing Schemes
Shared-risk or ‘pay for performance’ agreements between drugmakers and payers can represent uncertain rewards for both parties. Use strategic planning before entering into them